EP Patent

EP1836169B1 — Compositions and methods of treating cell proliferation disorders

Assigned to Athenex Inc · Expires 2012-02-08 · 14y expired

What this patent protects

The invention relates to compounds and methods for treating cell proliferation disorders.

USPTO Abstract

The invention relates to compounds and methods for treating cell proliferation disorders.

Drugs covered by this patent

Klisyri (TIRBANIBULIN) · Almirall

Patent Metadata

Patent number: EP1836169B1
Jurisdiction: EP
Classification: —
Expires: 2012-02-08
Drug substance claim: No
Drug product claim: No
Assignee: Athenex Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.